Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:IMMU

Immunomedics (IMMU) Stock Price, News & Analysis

Immunomedics logo

About Immunomedics Stock (NASDAQ:IMMU)

Key Stats

Today's Range
$87.86
$87.86
50-Day Range
$85.08
$87.86
52-Week Range
$8.80
$87.93
Volume
N/A
Average Volume
4.01 million shs
Market Capitalization
$20.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Receive IMMU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter.

IMMU Stock News Headlines

This is treason
If you missed it, my emergency election broadcast is now available - but will be removed soon
A Look At Gilead Sciences After Its Recent Weakness
See More Headlines

IMMU Stock Analysis - Frequently Asked Questions

Immunomedics, Inc. (NASDAQ:IMMU) announced its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.39. The biopharmaceutical company earned $20.07 million during the quarter, compared to analysts' expectations of $24.81 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunomedics investors own include Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Gilead Sciences (GILD) and Meta Platforms (META).

Company Calendar

Last Earnings
8/05/2020
Today
10/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IMMU
CUSIP
45290710
Fax
N/A
Employees
366
Year Founded
N/A

Profitability

Net Income
$-357,190,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$290,000.00
Price / Sales
70,028.66
Book Value
$1.38 per share

Miscellaneous

Free Float
N/A
Market Cap
$20.31 billion
Optionable
Optionable
Beta
2.90
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:IMMU) was last updated on 10/30/2024 by MarketBeat.com Staff
From Our Partners